An observational study in Thromboembolism and Cancer, sponsored by Fundación Sociedad Española de Oncologia Médica. Recruiting at 48 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-16.
Sponsored by Fundación Sociedad Española de Oncologia Médica · Observational
Epidemiological, observational, non-interventional, multicentric study on patients diagnosed with cancer who develop a venous or arterial thromboembolic episode, symptomatic or incidental, within a month prior to cancer diagnosis or at anytime after such diagnosis
288 studies on the registry are indexed under Thromboembolism; 42 are open to participants now.
This study's planned enrollment of 700 is above the median of 440 across 121 observational studies indexed under Thromboembolism.
Browse Thromboembolism studies →Fundación Sociedad Española de Oncologia Médica is the lead sponsor of 3 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Cancer patients
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Location of origin of the thromboembolytic event
Distribution in the number of patients according to the anatomical location affected by the thromboembolytic event.
Time frame: Baseline
Vessel of origin of the thromboembolytic event
Distribution in the number of patients according to the type of vessel affected by the thromboembolytic event.
Time frame: Baseline
Thromboembolytic event diagnosis type
Proportion of patients with incidental versus symptomatic thormboembolic events
Time frame: Baseline
Primary tumor at the time of the thromboembolic event
Distribution of patients according to the organ affected by the primary tumor.
Time frame: Baseline
Tumor-Node-Metastasis classification
Based on the American Joint Committee on Cancer 2018 Tumor-Node-Metastasis classification system: T for extent or size of the tumor, N for lymph nodes spread and M for metastasis.
Time frame: Baseline
Time between cancer diagnosis and thromboembolic event
Based on date on confirmed diagnosis of cancer (primary tumor) and date of thromboembolic event
Time frame: Baseline
Patient situation at the last visit
Number of patients with rethrombosis, bleeding, other complications, tumor progression or death.
Time frame: 12 months
Characteristics of treatment administered for cancer
Based on the number of patients prescribed with chemotherapy, radiation therapy, hormonal therapy, erythropoietin, transfusions, surgery, catheter, etc.
Time frame: Baseline
Plan to share: Undecided
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fundación Sociedad Española de Oncologia Médica